Drug Trial Radar · NCT06588491
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Sep 25, 2024
Primary completion
Jun 25, 2026
Study completion Jun 25, 2026
Sponsor
- Lead sponsor
- Kyverna TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome
Conditions
- Stiff-Person Syndrome
- SPS
Interventions
Standard lymphodepletion regimenBiological
Standard lymphodepletion regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate efficacy of KYV-101Time frame: Up to 12 months
- To evaluate the safety of KYV-101Time frame: Up to 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Colorado Anschutz Medical Campus
Aurora, Colorado
Mayo Clinic
Rochester, Minnesota
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.